Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a

Key Points Treatment with PEG-IFN-α-2a in PV and ET results in a high rate of complete hematologic and molecular responses. Patients failing to achieve complete molecular remission tended to have higher frequencies of mutations in genes other than JAK2.